2
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T1785 |
Palbociclib
PD 0332991,帕博西尼,帕布昔利布 |
CDK | Cell Cycle/Checkpoint |
Palbociclib (PD 0332991) 是一种 CDK 抑制剂,抑制 CDK4 和 CDK6 (IC50=11/16 nM),具有口服活性。Palbociclib 具有抗肿瘤活性,有用于 ER 阳性和 HER2 阴性乳腺癌的研究潜力。 | |||
T68389 | LY2457546 | ||
LY2457546 is a potent and orally bioavailable inhibitor of multiple receptor tyrosine kinases involved in angiogenic and tumorigenic signalling. LY2457546 demonstrates potent activity against targets that include VEGFR2 (KDR), PDGFRβ, FLT-3, Tie-2 and members of the Eph family of receptors. In vivo, LY2457546 inhibited VEGF-driven autophosphorylation of lung KDR in the mouse and rat in a dose and concentration dependent manner. LY2457546 was well tolerated and exhibited efficacy in a 13762 synge... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4S1849 |
Tubeimoside III
|
Others | Others |
Tubeimoside III 是一种具有抗炎和抗肿瘤活性的三萜皂苷,在体内具急性毒性。 | |||
TN5050 |
Sprengerinin C
|
NADPH-oxidase; VEGFR; p38 MAPK; ROS; Akt; PI3K; mTOR; p53 | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Immunology/Inflammation; MAPK; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis, it can strongly suppress tumor angiogenesis in human umbilical vein endothelial cells, it blocks vascul |